Selinexor — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

2 Recruiting

8 Completed trials

6 Sponsors

16 Countries

Phase III

Phase II

Phase I/II

Phase III: 5 Phase II/III: 1 Phase II: 4 Phase I/II: 2

Oversight events:

1 urgent safety measure across 1 trial

View oversight register →

Indications tested

Myelofibrosis 3 Thrombocytopenia 1 Adult T-cell lymphoma/leukaemia 1 Endometrial cancer metastatic 1 Primary myelofibrosis 1 Endometrial cancer 1 Adult T-cell lymphoma/leukaemia refractory 1 Adult T-cell lymphoma/leukaemia recurrent 1 Endometrial cancer recurrent 1

Sponsors using this IMP

Karyopharm Therapeutics Inc. 6 Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En Sarcomas 2 AbbVie Deutschland GmbH & Co. KG 1 European Myeloma Network B.V. 1 Fondazione IRCCS Istituto Nazionale Dei Tumori 1 University Medical Center Hamburg-Eppendorf 1

All trials

12 total

Clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas Not authorised

2024-514827-40-00 Phase I/II 1 country Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En Sarcomas
Clinical trial of selinexor plus gemcitabine in selected advanced soft-tissue sarcomas Pending

2024-520318-23-00 Phase I/II 1 country Asociacion Europea Y Latinoamericana SELNET Para La Investigacion En Sarcomas
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate… Recruiting

2024-511309-47-00 Phase II 13 countries Karyopharm Therapeutics Inc.
Selinexor, Dexamethasone and Bortezomib in Patients with Multiple Myeloma Recruiting

2024-511608-18-00 Phase II 1 country Karyopharm Therapeutics Inc.
A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended

2023-506668-15-00 Phase III 13 countries AbbVie Deutschland GmbH & Co. KG
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Phase III 13 countries Karyopharm Therapeutics Inc.
Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory… Ended

2024-513295-18-00 Phase II 1 country Fondazione IRCCS Istituto Nazionale Dei Tumori
Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa… Ended

2024-518304-53-00 Phase III 6 countries European Myeloma Network B.V.
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis Ended

2024-513605-31-00 Phase II 2 countries Karyopharm Therapeutics Inc.
Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Diffuse Large B-Cell Lymphoma Ended

2024-513616-95-00 Phase II/III 3 countries Karyopharm Therapeutics Inc.
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af… Ended

2024-510590-14-00 Phase III 1 country University Medical Center Hamburg-Eppendorf
Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Canc… Ended

2024-513167-68-00 Phase III 6 countries Karyopharm Therapeutics Inc.

Showing 1–12 of 12 trials

← All drugs A–Z